AZITHROMYCIN INCREASES CHLORIDE EFFLUX FROM CYSTIC FIBROSIS AIRWAY EPITHELIAL CELLS

REFERENCES

• Tarran R, Button B, Picher M, Paradiso A M, Ribeiro C M, Lazarowski E R, Zhang L, Collins P L, Pickles R J, Fredberg J J, Boucher R C. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005; 280: 35751–35759
   PubMed Web of Science ®Google Scholar
• Clunes M T, Boucher R C. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007; 4: 63–72
   PubMedGoogle Scholar
• Wang X, Kim J, McWilliams R, Cutting G R. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch Otolaryngol Head Neck Surg 2005; 131: 237–240
   PubMed Web of Science ®Google Scholar
• Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004; 10: 515–523
   PubMed Web of Science ®Google Scholar
• Southern K W, Barker P M. Azithromycin for cystic fibrosis. Eur Respir J 2004; 24: 834–838
   PubMed Web of Science ®Google Scholar
• Amsden G W. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 2005; 55: 10–21
   PubMed Web of Science ®Google Scholar
• Labro M T, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13: 3–8
   PubMed Web of Science ®Google Scholar
• Asgrimsson V, Gudjonsson T, Gudmundsson G H, Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother 2006; 50: 1805–1812
   PubMed Web of Science ®Google Scholar
• Labro M T, Babin-Chevaye C, Mergey M. Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated cystic fibrosis transmembrane conductance regulator protein (CFTR). J Chemother 2005; 17: 385–392
   PubMed Web of Science ®Google Scholar
• Gant T W, O'Connor C K, Corbitt R, Thorgeirsson U, Thorgeirsson S S. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995; 133: 269–276
   PubMed Web of Science ®Google Scholar
• Ambudkar S V, Dey S, Hrycyna C A, Ramachandra M, Pastan I, Gottesman M M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–398
   PubMed Web of Science ®Google Scholar
• Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237–262
   PubMed Web of Science ®Google Scholar
• Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006; 86: 1179–1236
   PubMed Web of Science ®Google Scholar
• Lallemand J Y, Stoven V, Annereau J P, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?. Lancet 1997; 350: 711–712
   PubMed Web of Science ®Google Scholar
• Barker P M, Gillie D J, Schechter M S, Rubin B K. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am J Respir Crit Care Med 2005; 171: 868–871
   PubMed Web of Science ®Google Scholar
• Equi A C, Davies J C, Painter H, Hyde S, Bush A, Geddes D M, Alton E W. Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med 2006; 100: 687–697
   PubMed Web of Science ®Google Scholar
• Pradal U, Delmarco A, Morganti M, Cipolli M, Mini E, Cazzola G. Long-term azithromycin in cystic fibrosis: another possible mechanism of action?. J Chemother 2005; 17: 393–400
   PubMed Web of Science ®Google Scholar
• Munkonge F, Alton E W, Andersson C, Davidson H, Dragomir A, Edelman A, Farley R, Hjelte L, McLachlan G, Stern M, Roomans G M. Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators. J Cyst Fibros 2004; 3(Suppl 2)171–176
   PubMedGoogle Scholar
• Ma T, Thiagarajah J R, Yang H, Sonawane N D, Folli C, Galietta L J, Verkman A S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651–1658
   PubMed Web of Science ®Google Scholar
• Broad L M, Cannon T R, Taylor C W. A non-capacitative pathway activated by arachidonic acid is the major Ca2 + entry mechanism in rat A7r5 smooth muscle cells stimulated with low concentrations of vasopressin. J Physiol 1999; 517: 121–134, (Pt 1)
   PubMed Web of Science ®Google Scholar
• Jentsch T J, Stein V, Weinreich F, Zdebik A A. Molecular structure and physiological function of chloride channels. Physiol Rev 2002; 82: 503–568
   PubMed Web of Science ®Google Scholar
• Schalling M, Franco-Cereceda A, Hemsen A, Dagerlind A, Seroogy K, Persson H, Hokfelt T, Lundberg J M. Neuropeptide Y and catecholamine synthesizing enzymes and their mRNAs in rat sympathetic neurons and adrenal glands: studies on expression, synthesis and axonal transport after pharmacological and experimental manipulations using hybridization techniques and radioimmunoassay. Neuroscience 1991; 41: 753–766
   PubMed Web of Science ®Google Scholar
• Schalling M. In situ hybridisation and immunohistochemical methods in study of regulatory molecules. Methods Neurosci 1992; 1: 231–255
   Google Scholar
• Hudson V M. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004; 3: 353–363
   PubMedGoogle Scholar
• Wang X, Venable J, LaPointe P, Hutt D M, Koulov A V, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, Riordan J R, Kelly J W, Yates J R, 3rd, Balch W E. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803–815
   PubMed Web of Science ®Google Scholar
• Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother 2000; 6: 1–7
   PubMedGoogle Scholar
• Berquand A, Fa N, Dufrene Y F, Mingeot-Leclercq M P. Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability. Pharm Res 2005; 22: 465–475
   PubMed Web of Science ®Google Scholar
• Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, Miyazaki Y, Hirakata Y, Mizuta Y, Kadota J, Iglewski B H, Kohno S. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother 2005; 49: 1377–1380
   PubMed Web of Science ®Google Scholar
• Berquand A, Mingeot-Leclercq M P, Dufrene Y F. Real-time imaging of drug-membrane interactions by atomic force microscopy. Biochim Biophys Acta 2004; 1664: 198–205
   PubMed Web of Science ®Google Scholar
• Fa N, Lins L, Courtoy P J, Dufrene Y, Van Der Smissen P, Brasseur R, Tyteca D, Mingeot-Leclercq M P. Decrease of elastic moduli of DOPC bilayers induced by a macrolide antibiotic, azithromycin. Biochim Biophys Acta 2007; 1768: 1830–1838
   PubMed Web of Science ®Google Scholar
• Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?. Curr Opin Pulm Med 2004; 10: 547–552
   PubMed Web of Science ®Google Scholar
• Saiman L, Mayer-Hamblett N, Campbell P, Marshall B C. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008–1012
   PubMed Web of Science ®Google Scholar
• Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212–216
   PubMed Web of Science ®Google Scholar
• Pirzada O M, McGaw J, Taylor C J, Everard M L. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. J Cyst Fibros 2003; 2: 69–71
   PubMedGoogle Scholar
• Hansen C R, Pressler T, Koch C, Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005; 4: 35–40
   PubMedGoogle Scholar
• Cigana C, Nicolis E, Pasetto M, Assael B M, Melotti P. Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients. J Chemother 2007; 19: 643–649
   PubMed Web of Science ®Google Scholar
• Gillis R J, Iglewski B H. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol 2004; 42: 5842–5845
   PubMed Web of Science ®Google Scholar
• Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61: 895–902
   PubMed Web of Science ®Google Scholar
• Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–229
   PubMed Web of Science ®Google Scholar
• Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, Galovic R, Glojnaric I, Manojlovic Z, Munic V, Novak-Mircetic R, Pavicic-Beljak V, Sucic M, Veljaca M, Zanic-Grubisic T, Parnham M J. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277–289
   PubMed Web of Science ®Google Scholar
• Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, Lison D, Scholte B J, Wallemacq P, Leal T. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006; 7: 134
   PubMed Web of Science ®Google Scholar
• Daenas C, Hatziefthimiou A A, Gourgoulianis K I, Molyvdas P A. Azithromycin has a direct relaxant effect on precontracted airway smooth muscle. Eur J Pharmacol 2006; 553: 280–287
   PubMed Web of Science ®Google Scholar